Viridian CMO exercises options for 40K shares

Viridian Therapeutics, Inc. (VRDN) reported that its Chief Medical Officer, Radhika Tripuraneni, exercised a stock option for 40,000 shares of common stock on 2026-08-14 at an exercise price of $13.21 per share.

Rhea-AI Filing Summary

Viridian Therapeutics, Inc. (VRDN) reported that its Chief Medical Officer, Radhika Tripuraneni, exercised a stock option for 40,000 shares of common stock on 2026-08-14 at an exercise price of $13.21 per share. The exercised option, which was fully vested, now shows 0 derivative shares remaining, and her directly held common stock position increased to 40,000 shares following the transaction.

Insider Trade Summary

40,000 shares exercised/converted

Exercise 2 txns

Insider Tripuraneni Radhika

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1	40,000	$0.00	$0.00
Exercise	Common Stock	40,000	$13.21	$528K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 40,000 shares (Direct)

Footnotes (1)

1. F1. The option is fully vested.

Key Figures

Option shares exercised: 40,000 shares Exercise price: $13.21 per share Common shares acquired: 40,000 shares +2 more

5 metrics

Option shares exercised 40,000 shares Stock Option (Right to Buy) exercised on 2026-08-14

Exercise price $13.21 per share Exercise price of stock option for 40,000 underlying common shares

Common shares acquired 40,000 shares Common stock position reported following the option exercise

Derivative shares remaining 0 shares Stock Option (Right to Buy) after full exercise

Option expiration date 2034-07-01 Expiration date of the exercised stock option grant

Key Terms

Stock Option (Right to Buy), derivative security, exercise price

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise price financial

"conversion_or_exercise_price: 13.2100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VRDN Chief Medical Officer Radhika Tripuraneni report?

Radhika Tripuraneni reported exercising a stock option for 40,000 shares of Viridian Therapeutics common stock at an exercise price of $13.21 per share on 2026-08-14. This converted her option position into directly held common shares.

How many VRDN shares did the insider hold after the reported Form 4 transaction?

After the transaction, Radhika Tripuraneni directly held 40,000 shares of Viridian Therapeutics common stock. The related stock option was fully exercised, leaving 0 derivative shares reported remaining from that grant.

What was the exercise price of the Viridian Therapeutics (VRDN) stock option exercised?

The stock option was exercised at $13.21 per share for 40,000 underlying common shares. This exercise converted the option, which was fully vested, into an equivalent number of directly owned common shares.

Did the VRDN insider transaction involve a sale of shares on the market?

The filing reports a stock option exercise and corresponding acquisition of 40,000 common shares, but it does not show any open-market sale (no sale transaction code such as “S” is reported).

When does the exercised Viridian Therapeutics (VRDN) stock option expire?

The exercised stock option had an expiration date of 2034-07-01. It was already fully vested at the time of the 2026-08-14 exercise, as disclosed in the footnote to the derivative transaction.

Was the VRDN Form 4 transaction under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not marked as true, and no footnote states that the option exercise occurred under a Rule 10b5-1 trading plan, based on the reported data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:34 PM Accepted by SEC EDGAR 08/18/2026 - 05:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tripuraneni Radhika

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		M		40,000	A	$13.21	40,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.21	08/14/2026		M			40,000	(1)	07/01/2034	Common Stock	40,000	$0.00	0	D

Explanation of Responses:

1. The option is fully vested.

	/s/ Jennifer Tousignant, Attorney-in-fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)